OptimizeRx Corp. announced a significant expansion of its point‑of‑care network with four new partner agreements that add an eRx platform previously part of a competitor’s network and a health‑systems access partner that delivers messages when treatment plans and patient instructions are finalized. The deals increase the company’s unique National Provider Identifier (NPI) reach by 37%, giving it access to a larger pool of healthcare providers and additional electronic health record (EHR) platforms.
The expansion strengthens OptimizeRx’s ability to embed its Dynamic Audience Activation Platform (DAAP) and Micro‑Neighborhood Targeting (MNT) capabilities directly into clinical workflows. By securing exclusive access to premium inventory and integrating these platforms into more provider touchpoints, the company is accelerating its transition from episodic managed services to recurring data contracts, a shift that is expected to lift gross margins and support a subscription‑based revenue model.
Prior quarter results underscore the momentum behind the expansion. In Q3 2025, OptimizeRx reported revenue up 22% year‑over‑year to $26.1 million and a gross margin of 67.2%, an increase from 63.1% in Q3 2024. The margin expansion reflects the higher mix of high‑margin subscription contracts and improved operational leverage as the platform scales, offsetting modest cost increases in support services.
CEO Steve Silvestro emphasized the strategic importance of the new partnerships, stating, “By deepening relationships with proven, high‑value partners and adding exclusive access to large‑scale platforms that were previously outside our network, we continue to position the Company for sustained, profitable growth.” The comment highlights management’s confidence that the expanded network will drive long‑term revenue growth and margin improvement.
The new agreements give OptimizeRx a competitive edge in the digital pharma marketing space, allowing the company to capture growing demand for in‑workflow engagement solutions. The exclusive access to premium inventory and the ability to embed DAAP and MNT into more clinical workflows position the company to capture higher‑margin subscription revenue and strengthen its moat against competitors.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.